argenx (NASDAQ:ARGX) had its price objective hoisted by equities research analysts at Stifel Nicolaus from $154.00 to $170.00 in a report released on Sunday, The Fly reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus’ price target would indicate a potential upside of 12.44% from the stock’s current price.
Other equities analysts also recently issued research reports about the company. ValuEngine downgraded argenx from a “hold” rating to a “sell” rating in a research report on Wednesday, October 2nd. William Blair raised argenx from a “market perform” rating to an “outperform” rating in a research note on Thursday, October 31st. Cowen started coverage on argenx in a report on Friday, September 13th. They set a “buy” rating for the company. Wells Fargo & Co started coverage on argenx in a report on Friday, September 27th. They set a “market perform” rating and a $125.00 price target for the company. Finally, Piper Jaffray Companies reissued an “overweight” rating on shares of argenx in a research report on Friday, November 8th. One analyst has rated the stock with a sell rating, three have issued a hold rating and twelve have issued a buy rating to the company’s stock. argenx currently has a consensus rating of “Buy” and an average target price of $160.08.
Shares of ARGX stock traded up $3.77 during trading hours on Friday, hitting $151.19. 640 shares of the company’s stock were exchanged, compared to its average volume of 148,138. argenx has a fifty-two week low of $88.05 and a fifty-two week high of $152.01. The firm has a market cap of $5.62 billion, a P/E ratio of -64.28 and a beta of 1.25. The firm has a 50 day moving average of $131.95 and a two-hundred day moving average of $131.46.
Institutional investors have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC purchased a new position in argenx in the third quarter valued at approximately $37,000. Marshall Wace LLP purchased a new position in shares of argenx during the first quarter worth approximately $121,000. Flinton Capital Management LLC acquired a new position in shares of argenx in the 2nd quarter valued at $156,000. Pacer Advisors Inc. acquired a new position in shares of argenx in the 3rd quarter valued at $128,000. Finally, First Trust Advisors LP purchased a new stake in argenx in the 2nd quarter valued at $212,000. 58.69% of the stock is owned by institutional investors and hedge funds.
argenx Company Profile
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
Recommended Story: What are catch-up contributions?
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.